Core Insights - YD Bio Limited is expanding its OkaiDx platform for cancer detection, now including pancreatic and colorectal cancer tests in addition to breast cancer monitoring [1][2] - The company has established partnerships to integrate OkaiDx testing into primary care and women's health settings, enhancing accessibility for proactive cancer detection [3] - Recent clinical data shows the OkaiDx Detect Pancreatic Cancer Test has high sensitivity and specificity, indicating its potential effectiveness in early-stage cancer detection [4] Company Developments - YD Bio has broadened the availability of its OkaiDx blood-based testing services across 44 states in the U.S. through EG BioMed's accredited laboratory [2] - The company is leveraging a nationwide telehealth network to facilitate virtual consultations and streamline blood sample collection for patients [2] - New memorandums of understanding with medical groups aim to incorporate OkaiDx testing into routine clinical workflows [3] Clinical Advancements - The OkaiDx Detect Pancreatic Cancer Test demonstrated 93.8% sensitivity for early-stage pancreatic ductal adenocarcinoma and 100% sensitivity for late-stage cases [4] - The test also showed 97.3% specificity in healthy individuals and 97.7% overall accuracy in a study involving 100 PDAC patients and 500 healthy controls [4] - The findings highlight the potential of cfDNA methylation biomarkers, such as ZFP30, in improving early cancer detection [4]

Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its support for the global commercialization of OkaiDx™, a research‑use‑only (RUO) blood test for post‑treatment breast cancer monitoring now available through the Company’s affiliate EG Biomed US Inc. (“EG BioMed”)’s CLIA/CAP‑certified laboratory in the United States. ...